Interventions for muscular dystrophy: molecular medicines entering the clinic.
Muscular dystrophies are individually rare genetic disorders that cause much chronic disability, affecting young children and adults. In the past 20 years, more than 30 genetic types of muscular dystrophy have been defined. During this time, precise diagnosis, genetic counselling, and medical management have improved. These advances in medical practice have occurred while definitive therapies based on an improved knowledge of disease pathogenesis are awaited. A wide range of therapeutic options have been tested in animal models, and some are being tested in clinical trials. Various therapeutic targets are being investigated, from personalised medicines targeting specific mutations and drugs targeting cellular pathways to gene-based and cell-based therapies.
Bushby
Kate
K
Institute of Human Genetics, Newcastle University, Newcastle upon Tyne, UK. kate.bushby@ncl.ac.uk
Lochmüller
Hanns
H
Lynn
Stephen
S
Straub
Volker
V
D000818:Animals; D004195:Disease Models, Animal; D016189:Dystrophin / Q000235:genetics*; D015316:Genetic Therapy; D006801:Humans; D051379:Mice; D009136:Muscular Dystrophies / Q000188:drug therapy* / Q000235:genetics* / Q000628:therapy*; D009154:Mutation; D011506:Proteins / Q000627:therapeutic use
D016189:Dystrophin; D011506:Proteins